CD8A and hepatocellular carcinoma: Third, due to the limitation of detailed therapeutic information of all the HCC and ICC patients involved in the present study, it is of great importance to evaluate the predictive value of tissue-resident CD103+CD8+T cells for therapeutic efficacy of target therapy or immunotherapy against HCC or ICC.